CA2574500A1 — D-pyranosyl-substituted phenyls, medicaments containing said compounds, use thereof, and method for the production thereof
Assigned to Boehringer Ingelheim International GmbH · Expires 2006-04-13 · 20y expired
What this patent protects
D-pyranosyl-substituted phenyls of general formula I wherein the groups R<SUP>1 </SUP>to R<SUP>5</SUP>, X, Z and R<SUP>7a</SUP>, R<SUP>7b</SUP>, R<SUP>7c </SUP>are defined as in claim 1, have an inhibiting effect on the …
USPTO Abstract
D-pyranosyl-substituted phenyls of general formula I wherein the groups R<SUP>1 </SUP>to R<SUP>5</SUP>, X, Z and R<SUP>7a</SUP>, R<SUP>7b</SUP>, R<SUP>7c </SUP>are defined as in claim 1, have an inhibiting effect on the sodium-dependent glucose cotransporter SGLT. The present invention also relates to pharmaceutical compositions for the treatment of metabolic disorders.
Drugs covered by this patent
- Jardiance (empagliflozin) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.